Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm)
A Single center, Open, Randomized Controlled Trial Evaluating the Safety and Efficacy of GSMs-TACE combined with Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm).
Huge Hepatocellular Carcinoma (HCC) (≥10cm)
DEVICE: GSMs-TACE|PROCEDURE: Surgical Resection
Disease Free Survival（DFS）, 6 months|Median Overall Survival (mOS), 2 years
Incidence of Intrahepatic Metastasis, 6 months|Incidence of Extrahepatic Metastasis, 1 and 2 years|Overall Survival (OS), 1 and 2 years|Adverse Events, 6 months
A Single center, Open, Randomized Controlled Trial Evaluating the Safety and Efficacy of GSMs-TACE combined with Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm).